Tsutomu Murakami

TL;DR: Results indicate that BCA2 accelerates the internalization and degradation of viral particles following their tethering to the cell surface and is a co-factor or enhancer for the tetherin-dependent restriction of HIV-1 release from infected cells.

TL;DR: KRH-3955 is a new promising agent for HIV-1 infection and AIDS that is bioavailable when administered orally with much more potent anti-HIV-1 activity than AMD3100 and KRH-1636.

TL;DR: Stapled peptides, a new class of stabilized α-helical peptidomimetics were adopted to enhance the cell permeability of the above lead peptides and led to a remarkable increase in their potency in cells and a significant reduction of their cytotoxicity.

TL;DR: The discovery of coreceptors provides a more defined scheme for virus entry in which the HIV-1 envelope glycoprotein sequentially binds CD4 and coreceptor, leading to a membrane fusion reaction between the viral envelope and the plasma membrane of the target cell.

TL;DR: Several new zinc(II) or copper( II) complexes demonstrated potent anti‐HIV activity, strong CXCR4‐binding activity, and significant inhibitory activity against Ca2+ mobilization induced by CXCL12 stimulation, which may prove useful in the design of novel CX CR4 antagonists.